Peptidream Inc. announced a new multi-target collaboration and license agreement with Merck & Co. Inc., known as MSD outside the U.S. and Canada, as well as research collaboration and license agreement with Eli Lilly & Co (Lilly). Both agreements are focused on the discovery and development of novel peptide drug conjugates (PDCs). Under the agreement with MSD, Peptidream will provide peptide candidates identified from its proprietary Peptide Discovery Platform System (PDPS) technology for use as PDCs against targets of interest to MSD.

Merck & Co. Inc. and Kelun-Biotech, a holding...

Ethris GmbH has entered into a collaboration with Diosynvax Ltd. to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses utilizing the company's highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms.

Poolbeg Pharma plc has identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with Onethree Biotech Inc.

Ordaōs Bio Inc. has entered into a joint development agreement with Yatiri Bio Inc. to create new therapeutics for two novel targets in acute myeloid leukemia (AML).